Digital Biotechnologies Raises Series A to Advance Next‑Generation Clinical Sequencing Technology
Digital Biotechnologies, a newly formed Seattle‑based clinical sequencing and biotechnology startup spun out of publicly traded Adaptive Biotechnologies, has raised fresh capital as part of its initial Series A funding round, with up to $15 million anticipated in total proceeds to advance its next‑generation DNA sequencing technology. The financing—closed at an initial tranche late in 2025—represents a major step for the early‑stage company as it seeks to build clinical sequencing instruments that combine high accuracy, rapid turnaround, and lower costs than existing platforms tailored for broad clinical use.
Digital Biotechnologies was created with backing from its parent company Adaptive Biotechnologies, which currently owns approximately 70 percent of the spin‑out and expects to retain nearly 50 percent ownership once the Series A round completes. Adaptive, a leader in immune medicine and minimal residual disease (MRD) testing tools, will continue to consolidate Digital Biotechnologies’ results in its own financial reporting, underscoring its strategic support for the venture.
The mission of Digital Biotechnologies centers on developing a solid‑state sequencing instrument that addresses longstanding limitations in high‑throughput DNA sequencing—chiefly the need for devices that deliver clinical‑grade performance with faster turnaround and more affordable operational costs. By leveraging insights, engineering expertise, and intellectual property drawn from Adaptive’s immune medicine research, Digital Biotechnologies aims to bring next‑generation sequencing capabilities to settings where current systems fall short.
Industry observers note that while existing next‑generation sequencing technologies have transformed genomics research and certain diagnostic applications, many platforms lack the combination of speed, precision, and cost‑effectiveness needed for point‑of‑care and broader clinical workflows. Digital Biotechnologies’ efforts to engineer a new class of clinical sequencers could position it to meet demand from hospitals, diagnostic labs, and clinicians seeking high‑throughput yet rapid diagnostics.
The startup operates out of Adaptive Biotechnologies’ headquarters in Seattle’s South Lake Union neighborhood, tapping into the Pacific Northwest’s renowned life sciences ecosystem. Though details about its leadership team beyond ownership structure have been limited in public filings, Digital Biotechnologies lists several employees on professional networks working on engineering and product development, including initiatives to design a hardware platform optimized for clinical utility.
According to job postings and industry reporting, the company’s product vision involves collaborative development with academic and industry scientists across the country, combining expertise in engineering, genomics, and clinical diagnostics to build a sequencer that can support a wide range of applications from infectious disease testing to genetic analyses in oncology and inherited disorders.
The Series A financing comes at a time of heightened interest in clinical genomics innovation, with investors and strategic partners increasingly focused on tools that can deliver actionable insights in healthcare settings. While Digital Biotechnologies’ funding details beyond the anticipated total have not been fully disclosed, the size of the round signals strong confidence in the company’s technology roadmap and the potential for its sequencing platform to make an impact on diagnostic workflows.
As part of its strategic positioning, Digital Biotechnologies will continue to leverage its affiliation with Adaptive Biotechnologies—a company founded in 2009 and publicly traded since 2019—to gain access to expertise in immune system‑based diagnostics and commercial infrastructure. Adaptive’s experience in translating complex biological data into clinical tools has helped lay the groundwork for Digital Biotechnologies’ ambitions in the clinical sequencing space.
With the initial Series A funding secured, Digital Biotechnologies plans to invest in engineering development, prototype validation, and expanding its team to accelerate progress toward a commercially viable instrument. Industry analysts say the company’s work could resonate with global healthcare providers seeking sequencing technologies that balance clinical performance, throughput, and cost—an objective that remains a central challenge in modern diagnostics.
The anticipated $15 million round reflects broader investor and strategic interest in biotechnology innovation at the intersection of hardware and clinical genomics, a space that has seen increased prioritization as healthcare systems adopt genomics‑based approaches for disease detection, treatment personalization, and population health management.
As Digital Biotechnologies moves forward with its development roadmap, the company will continue to refine its technology and build toward future funding milestones that support larger scale deployments—an effort that aligns with ongoing shifts in how genomic data is gathered, interpreted, and applied to improve patient outcomes in clinical settings.
